$SRPT,,This stock is on the BioPharma Update which
Post# of 22755
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are trading up 14% in the after-hours session to $38.70 following better than expected sales data reported in its 2Q earnings release. Sales from Exondys 51, approved by the FDA in 2016 for the treatment of Duchenne muscular dystrophy, were $35m in 2Q 2017, above market estimates of around $22m. Guidance was also raised for 2017 to between $125m and $130m, above previous consensus of $105m.
https://twitter.com/twitter/statuses/957208055766241280